NCT06429969 Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.
| NCT ID | NCT06429969 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Renmin Hospital of Wuhan University |
| Condition | Vitreoretinal Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2024-01-17 |
| Primary Completion | 2027-04-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2024-01-17 with a primary completion date of 2027-04-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.
Eligibility Criteria
Inclusion Criteria: 1. Confirmation of IMH diagnosis with concomitant need for PPV surgery; 2. Confirmation of DR diagnosis with concomitant need for PPV surgery; 3. Confirmation of RD diagnosis with concomitant need for PPV surgery; 4. Confirmation of IMM diagnosis with concomitant need for PPV surgery; 5. Confirmation of RVO diagnosis with concomitant need for PPV surgery. Exclusion Criteria: 1. Diagnosed vitreoretinal disease with no need for PPV surgery; 2. Previous history of PPV surgery; 3. Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis; 4. Combination of serious systemic diseases such as hypertension and diabetes mellitus.
Contact & Investigator
Lei Du
PRINCIPAL INVESTIGATOR
Renmin Hospital of Wuhan University
Frequently Asked Questions
Who can join the NCT06429969 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 90 Years, studying Vitreoretinal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06429969 currently recruiting?
Yes, NCT06429969 is actively recruiting participants. Contact the research team at wdrmiit@163.com for enrollment information.
Where is the NCT06429969 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06429969 clinical trial?
NCT06429969 is sponsored by Renmin Hospital of Wuhan University. The principal investigator is Lei Du at Renmin Hospital of Wuhan University. The trial plans to enroll 450 participants.